One recent study of the genomic and transcriptomic features of the response of metastatic melanoma to anti-programmed cell death protein 1 (PD-1) therapy revealed that a transcriptional signature is related to innate anti-PD-1 resistance (24). This evidence concerns the gene PDCD1 and metastatic melanoma.